Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

NCT00711035 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00711035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00711035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2008
Completion date
August 31, 2013
Enrollment
50 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infection, ebv infection